Disease Markers

Review Article

TRPV2: A Cancer Biomarker and Potential Therapeutic Target

Table 1

TRPV2 agonists and antagonists.


	Activators	Inhibitors

Activity	Heat (≥52°C), CBD, CBN, probenecid, IGF-1, THC, THCV, INS, Δ9-THC, PDGF, NHA, LPC, LPI, 2-APB, fMet-Leu-Phe (fMLP)	SKF96365, tranilast, amiloride, Gd³⁺, RR
Traffick	CBD, IGF-1, INS, LPC, LPI, PDGF, NHA, fMet-Leu-Phe (fMLP)
Expression	IGF-1, INS	SKF96365, tranilast, PMA

Translocation of TRPV2 from cytoplasm to plasma membrane. CBD: cannabidiol; THC: (-)-trans-Δ9-tetrahydrocannabidol; CBN: cannabinol; THCV: Δ9-tetrahydro-cannabivarin; NHA: neuropeptide head activator; PDGF: platelet-derived growth factor; IGF-1: insulin-like growth factor-1; PMA: phorbol-12-myristate-13-acetate; RR: ruthenium red; Gd³⁺: gadolinium; LPC: lysophosphatidylcholine; LPI: lysophosphatidylinositol; 2-APB: 2-aminoethoxydiphenyl borate; fMLP: fMet-Leu-Phe; INS: insulin; tranilast: N-[3,4-dimethoxycinnamonyl]-anthranilic acid; SKF96365: 1-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl-1H-imidazole.